Max Healthcare Q1 FY27 Earnings Call Transcript Released
Max Healthcare Institute Limited released its Q1 FY27 earnings call transcript. The company reported 16% year-on-year revenue growth to INR 2,982 crore and 15% EBITDA growth to INR 704 crore. Key expansion projects include a new 202-bed tower at Max Vaishali with INR 425 crore capex. The company is also venturing into the medical education business.
The announcement details significant financial performance, substantial capital expenditure for expansion, strategic diversification into a new business vertical (medical education), and provides updates on ongoing projects, all of which have a material impact on the company's future prospects.
The company reported strong year-on-year growth in revenue and EBITDA, highlighted successful execution of expansion plans, and announced a strategic move into the medical education business, all contributing to a positive outlook.
Max Healthcare Institute Limited has released the transcript of its earnings conference call held on August 14, 2026, discussing the financial results for the quarter ended June 30, 2026. The company reported a healthy momentum with a year-on-year growth of 16% in revenue and 15% in operating EBITDA for the quarter.
During the call, the management highlighted the execution of ongoing capacity expansion plans. At Max Smart, 50% of the 400-bed capacity is operational, with the remainder expected to be handed over this quarter. Nanavati Max will also operationalize its remaining 50 beds this quarter, with Phase 2 expansion commencing.
The integration of Max Bhubaneswar is proceeding as planned, contributing INR 19 crore in revenue and INR 2 crore in EBITDA post-acquisition. The company also announced a capital expenditure of INR 425 crore for a new 202-bed brownfield tower at Max Vaishali, expected to be commissioned before FY30.
Max Healthcare is strengthening its research and academic ecosystem with the establishment of a standalone Max Research Centre and has received several research grants. The Max Institute of Medical Education (MIME) trains over 12,000 healthcare professionals annually. The company has received in-principle board approval to embark upon the medical education business, anticipating it to be a significant line of business.
Performance highlights for Q1 FY27 include an average occupancy of over 75%, Occupied Bed Days (OBDs) up by 10% year-on-year, and Average Revenue Per Occupied Bed (ARPOB) at INR 81,900, growing by 5%. Network gross revenue stood at INR 2,982 crore, a 16% year-on-year increase. Network operating EBITDA was INR 704 crore, a 15% year-on-year growth, with an operating EBITDA margin of 24.8%. Profit after Tax (PAT) for the Network was INR 357 crore.
The company generated free cash flows of INR 397 crore, deploying INR 386 crore towards acquisitions and INR 337 crore in capacity expansion projects. Net debt stood at INR 2,384 crore, with a net debt-to-EBITDA ratio below 1.
Strategic business units Max@Home and Max Lab reported revenues of INR 78 crore (32% growth) and INR 58 crore (20% growth) respectively. Several expansion projects are underway, with phased commissioning expected over the next few years across various locations including Lucknow, Gurgaon, Bhubaneswar, Nagpur, Zirakpur, Dwarka, Pitampura, Patparganj, Nanavati, and Pune.
During the Q&A session, management discussed the turnaround plans for Kalinga Hospital, capacity expansion at Max Smart and Nanavati Max, potential impact of the Parliamentary Standing Committee's recommendations on the healthcare sector, and the strategy for entering the medical education business, projecting ROCEs of over 25-30%. They also addressed the impact of oncology drug discontinuation and the normalization of oncology segment from Q3 FY27 onwards. Discussions also covered CGHS benefits, insurance negotiations, and the bookkeeping of free cash flow, attributing the difference to movements in accounts receivable.
What to do with a filing like this
Max Healthcare Institute Limited filed this with the NSE as a statutory disclosure, categorised under concall transcript released. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Max Healthcare Institute Limited. Read the original for the full detail.